BioBusiness

Because of the complexity of the manufacturing processes for biologics, transfer of these processes to a contract manufacturer presents challenges.

Social media use raises questions about applying old standards to new information technology.

Key business considerations when developing biosimilar products virtually.

Has the long-awaited guidance answered all of the industry's questions?

This month, we rewind to an article titled "Demystifying the New Biology."

Key technical considerations when developing a clinical project in the biotech world.

New educational programs are key to the industry's future and to safe, available drugs.

Industry announces plans for year ahead at annual JPMorgan Global Healthcare Conference.

Introducing a new way to think about sharing information in a patent-driven industry.

The benefits of harmonization may be on industry's wish list, but buying into change is another story.

Government plans require investment, partnership, and industry collaboration.

Greater emphasis on focus and efficiency for companies as market demands value in 2012.

Political leaders need to consider the impact of the biopharmaceutical industry on the economy.

With the rise in therapeutics comes more complex partnerships.

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Inside the National Institutes of Health

Market considerations and new technologies must be recognized to achieve the full benefits of manufacturing prefilled syringes.

An interview with Oskar Gold, vice-president, key account management and corporate marketing, at Vetter.

The market landscape for biosimilars is in flux, with limited penetration now, but with the potential for growth for those who can navigate the market. Plus: A SWOT analysis of biosimilars by Anjan Selz.

FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.

Industry may be its own obstacle to success in achieving the desired high-performance state.

Are biosimilars the next big thing or just the next big bubble?

Insights from real-time ranking of global biomanufacturing capabilities.

Which route will we take to arrive at a national stem-cell policy?

Strong pipelines, approvals, and deals drive up market cap.

BIO's president and CEO provides insight leading up to the 2011 convention.

Patent databases are often overlooked as a source of basic science, research, and development

Knowing where key biomanufacturing facilities are located around the world is essential for decision-making.

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Two films portray, in surprising detail, the hard work and determination of the biopharmaceutical industry.